Bioxyne Delivers Australia’s First Pharmaceutical Cannabis Gummies, Scales Up Manufacturing Capabilities
Australian life sciences and health products company Bioxyne Limited (ASX: BXN) announced Wednesday that its fully-owned subsidiary, Breathe Life Sciences (BLS), has successfully manufactured and delivered Australia’s first pharmaceutical-grade cannabis edibles. These new gummies carry Good Manufacturing Practice (GMP) certification from the Therapeutic Goods Administration (TGA). This milestone marks a significant advancement in the domestic production and availability of medicinal marijuana products in Australia.
“BLS is the first Australian manufacturer to complete a commercial production run of pharmaceutical grade GMP-certified THC gummies,” stated Sam Watson, founder & CEO of BLS and Managing Director of BXN. “As a leading Australian cannabis manufacturer, we are supplying our pharmaceutical goods to both domestic and international markets, using established relationships and existing supply channels.”
In July 2024, BLS received deposits on purchase orders totaling approximately AU$2million ($1.35 million) for cannabis gummies, containing both cannabidiol (CBD) and/or delta-9-tetrahydrocannabinol (THC). …